Cambridge Enterprise and European Molecular Biology Laboratory have presented new peptides derived from full-length factor V (FV) protein acting as T-cell activation inhibitors reported to be useful for the treatment of inflammatory bowel disease, type 1 diabetes, systemic lupus erythematosus, psoriasis, vasculitis, idiopathic pulmonary fibrosis, vitiligo and lupus nephritis, among other disorders.